Screener
Sarepta Therapeutics, Inc. SRPT Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Net margin | -6.9%— | 3%— | -32.5%— | —— | —— | |
| Returns | ||||||
| Return on equity | -9.3%-4.7pp | 4.8%+27.9pp | -53.5%-73.2pp | -21.4%-29.0pp | -4.7%-4.9pp | |
| Efficiency | ||||||
| Asset turnover | 0.6×— | 0.7×— | 0.6×— | —— | —— | |
| Liquidity | ||||||
| Current ratio | 4.4×+1.5× | 4.6×+0.6× | 2.3×-1.9× | 3×-0.9× | 2.9×-1.0× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×0.0× | 0.2×0.0× | 0.2×-0.1× | 0.2×-0.1× | |
| Per Share | ||||||
| Book value per share | $14.49+10.0% | —— | —— | —— | $13.18— | |
| Valuation | ||||||
| Market capitalization | $1.77B+10.9% | $2.28B-63.1% | $2.26B-80.6% | $2.02B-82.9% | $1.87B-87.4% | |
| Price / sales | 0.9×— | 1×— | 1×— | —— | —— | |
| Price / book | 1.2×0.0× | 1.5×-3.7× | 2×-5.6× | 1.5×-8.1× | 1.3×-12.5× |
FAQ
- Where do Sarepta Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Sarepta Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
